A renin-angiotensin level that is inappropriately high for the systemic blood pressure and the state of sodium balance is now recognized to be one of the modifiable cardiovascular risk factors. Angiotensin acts both as a circulating hormone and as a locally acting paracrine/autocrine/intracrine factor. The adverse effects of angiotensin on the heart include the mechanical results of elevated resistance to the pumping function of the myocardium, as well as the effects of neurohumoral abnormalities on various cardiac structures. In addition, cardiac damage follows acute ischaemic injury or chronic energy starvation due to coronary artery disease, attributable to either mechanical obstruction Keywords: angiotensin II; renin-angiotensin system; cardiovascular disease; myocardial infarction
Myocardial ischaemia
Angiotensin II (A II) is one of the major systemic pressor hormones (others include noradrenaline, vasopressin and endothelin). The idea that excessive levels of circulating A II can cause myocardial infarctions originated from an early experiment in which exogenous infusion of A II produced widespread areas of myocardial necrosis in rabbits. 1 Clinical observations in patients subjected to extreme stimulation of the renin-angiotensin system during haemodialysis revealed that these patients were prone to coronary death. This was attributed to intense coronary vasoconstriction, because focal myocardial necrosis was described in areas with no detectable coronary obstructive lesions. 2 These experiments were later replicated and amplified by other investigators. 3, 4 It was found that an excess of endogenous or exogenous A II can damage the myocardium via several additional mechanisms, such as increased sarcolemmic permeability and death of cardiac myocytes, or increased permeability and destruction of coronary microvascular endothelial cells. All these eventually lead to the replacement of contractile myocardium by fibrotic tissue.
Angiotensin II exerts a preferential pressor action on the coronary, renal, cerebral and adrenal vascula-tures. This was first demonstrated in a series of experiments in dogs submitted to endogenous A II stimulation. [5] [6] [7] Blockade of A II by either a competitive antagonist or an angiotensin-converting enzyme (ACE) inhibitor produced a redistribution of regional blood flows favouring those vascular trees most sensitive to A II-induced vasoconstriction. In fact, under conditions of a stimulated renin-angiotensin system, A II blockade produced vasodilation in the heart, kidney and brain at the expense of musculocutaneous tissues. The validity of these results was confirmed in humans, in whom coronary dilation in response to A II blockade was found to correlate with the level of plasma renin activity, regardless of oxygen demand, which meant that it could override the autoregulatory mechanisms of coronary perfusion. 8 Subsequent clinical studies have corroborated the capacity of ACE inhibition to enhance the coronary blood flow, especially in the absence of fixed anatomical obstruction, 9, 10 and have demonstrated the anti-anginal effect of this treatment in patients with symptomatic coronary insufficiency. [11] [12] [13] [14] Essentially, these data establish angiotensininduced vasoconstriction as an independent mechanism capable of inducing permanent myocardial injury in the absence of atherosclerotic or thrombotic coronary obstruction. The widespread necrotic lesions resulting from these prolonged vasospastic episodes can initiate the sequence of events leading eventually to heart failure and/or sudden death.
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Left-ventricular hypertrophy
Left ventricular hypertrophy (LVH) develops as an adaptive response of the normal heart to an increased workload. Hypertension causes LVH in up to 50% of patients evaluated by echocardiography. 15 As a potent pressor and steroidogenic hormone, A II raises blood pressure (BP) by increasing peripheral vascular resistance and retaining sodium and fluid. This causes left-ventricular wall tension, leading to adaptive changes in creatine kinase isoenzymes and alterations in isomyosin patterns. 16 The haemodynamic burden is, however, only one of the factors affecting left-ventricular wall thickness. This is shown by the poor correlations between magnitude of LVH and severity or duration of hypertension, as well as the poor correlation between normalization of BP and regression of LVH. It is now recognized that several neurohumoral factors activated by the hypertensive process (or by certain antihypertensive treatments) can contribute to the development of LVH.
Angiotensin II exerts several direct effects on the heart via activation of the angiotensin type-1 receptor (AT 1 receptor), which is a G-protein-linked receptor identified on cardiac myocytes that activates protein kinase C through formation of diacylglycerol and hydrolysis of phosphatidylinositol.
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The positive inotropic, mitogenic and arrhythmogenic actions of A II are now well documented. 19, 20 It stimulates both hypertrophy and hyperplasia of cardiac myocytes as well as vascular smooth-muscle cells by activating proto-oncogenes, which is one of the early steps in cell hypertrophy and division. Intracellular second messengers generated by stimulation of AT 1 receptors, such as phospholipases and phosphatidic acid, are now known to enhance mitogenesis; they were shown to increase thymidine incorporation in various cells, 21, 22 and induce mRNA expression of c-fos and c-myc. 23 In fact, a close correlation has been reported in experimental animals between LVH and myocardial levels of A II. 24 In addition to its direct action of stimulating protein synthesis and cell proliferation, A II has also been shown to release other growth factors from smooth-muscle cells and blood cells, such as the platelet-derived growth factor. Furthermore, it enhances peripheral sympathetic activity and exerts a permissive action on the release of noradrenaline, 25 which possesses trophic properties of its own and promotes myocardial cell growth and hypertrophy. 26 One issue that is still controversial is the role of circulating vs locally generated A II on myocardial cell growth and proliferation. 27, 28 It is currently unclear to what extent these effects of A II are attributable to the hormone formed in the circulation by renin of renal origin, to the interstitially diffused paracrine or autocrine A II supposedly generated from components of local origin, or even to Journal of Human Hypertension a possible intracrine action of intracellularly generated A II.
Angiotensin type-2 receptors are also present on the surface of various human cells such as brain and kidney, and are believed to regulate foetal growth and development, 29 but their numbers diminish rapidly in the postnatal period and their function after birth remains obscure.
Oxidative stress
In addition to vasoconstriction-induced myocardial ischaemia, A II promotes myocardial damage by affecting normal oxygen metabolism. This exerts both direct deleterious effects on myocardial (and other) cells, and indirect effects via enhanced lipid peroxidation and atherogenesis leading to coronary artery disease.
Angiotensin II causes increased activity of the NADH and NADPH oxidases, with production of large amounts of superoxide anions. 30 The data suggest that reactive oxygen intermediates may be part of the normal intracellular signalling responses following stimulation of AT 1 receptors. Reactive oxygen species are known to cause oxidative damage to various cellular structures, including membranes, proteins such as intracellular enzymes, DNA sequences and DNA repair enzymes. 31 Acute myocardial infarction is accompanied by activation of numerous systemic and local neurohumoral factors, including the renin-angiotensin system. 32, 33 Furthermore, reperfusion of the acutely infarcted area (as obtained experimentally by removal of a coronary ligature and clinically by thrombolytic agents) produces a surge in reactive oxygen species, causing tissue damage beyond that inflicted by ischaemia 34 and partially attributed to activation of local humoral factors, including A II. Inhibition of ACE was shown to minimize the extent of this damage, 35, 36 although it is unclear how much of this benefit should be attributed to A II suppression and how much to potentiation of bradykinin.
Another type of oxidative damage that is relevant to coronary heart disease is lipid peroxidation, which is the auto-oxidation of polyunsaturated fatty acid chains of lipids. 37 Recent evidence indicates that low-density lipoprotein (LDL) cholesterol has to be oxidized before it becomes atherogenic, and that lipid peroxidation is the first step in this process.
Oxidized LDL is taken up by macrophages, stimulates monocyte adhesion to the endothelium, inhibits vasodilation and is generally cytotoxic. 38 Recent clinical work suggests that LDL cholesterol derived from hypertensive patients has an increased susceptibility to lipid peroxidation, which the authors attributed to A II because it could be reduced by ACE inhibition. 39 This mechanism would partly explain the increased tendency of hypertensive patients to develop atherosclerotic changes, leading to coronary obstruction as well as peripheral vascular obstructive disease. In fact, there is epidemiological evidence to suggest that highrenin-hypertensive patients are significantly more prone to heart attacks 40, 41 and to coronary disease in general. Moreover, successful treatment of hypertension by most conventional medications (mostly diuretics, which are known to stimulate the reninangiotensin system) was shown to significantly decrease the incidence of complications such as renal failure, heart failure and stroke, but not that of myocardial infarctions. 42 Although no such studies are available for newer antihypertensive agents such as ACE inhibitors and A II blockers, ACE inhibitors have demonstrated anti-atherogenic properties. 43 More importantly, in trials of patients with preexisting ischaemic heart disease or heart failure, such as the Survival And Ventricular Enlargement (SAVE) and Studies Of Left Ventricular Dysfunction (SOLVD) studies, ACE inhibition was found to reduce the rate of myocardial infarctions by up to 25%.
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Coagulation-fibrinolysis equilibrium
Normal blood rheology depends on the constant equilibrium between forces that enhance intravascular coagulation and intrinsic thrombolytic factors. Disturbance of this process, by inhibitors of the tissue-type plasminogen activator (t-PA), for example, will tilt the balance towards increased thrombogenesis. 47 In fact, elevated levels of the PA inhibitor-1 (PAI-1) have been implicated in the pathogenesis of thromboembolic diseases in general, 48 and are considered to be a risk factor and/or marker for recurrence of myocardial infarction. 49 Angiotensin II was reported to induce secretion of PAI-1 from cultured cells in vitro. 50 In vivo infusions of A II in both hypertensive patients and normotensive control subjects were found to induce a rapid dose-dependent increase in circulating levels of PAI-1. 51 The finding that A II enhances endothelial synthesis and secretion of PAI-1 suggests an additional mechanism by which activation of the renin-angiotensin system may increase the risk of coronary events. These data are consistent with the epidemiological studies linking high-renin hypertension to increased risk of heart attack, as mentioned earlier.
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Arrhythmogenic potential of angiotensin II
A high density of A II receptors has been demonstrated in the conduction system of the heart. 52 Stimulation of such receptors on the sino-atrial and atrioventricular nodes and the Purkinje fibres can generate spontaneous electrical activity or alter responses to electrical stimulation. 53 This effect is believed to be mediated via activation of protein kinase C and increased calcium current resulting from altered conductance of calcium channels. 18, 54 It has been demonstrated that A II shortens the refractory period in cardiac myocytes. 55 Activation of AT 1 receptors of A II was also demonstrated to stimulate the release of endothelin-1, 56 itself believed to be arrhythmogenic.
In addition to this direct mechanism, A II exerts an indirect pro-arrhythmic effect by enhancing sympathetic activity and suppressing vagal activity. Facilitation of sympathetic neurotransmission in cardiac adrenergic nerve terminals 57 and sympathetic ganglia 58 is partly responsible for the positive inotropic, chronotropic and pro-arrhythmic properties of A II. Furthermore, an inhibitory action of A II on cardiac vagal afferents in the central nervous system has been reported. 59 Disequilibrium between sympathetic and parasympathetic influences is one of the characteristics of decompensated chronic heart failure (CHF), which is associated with activation of the sympathetic system and the renin-angiotensin system. This autonomic imbalance with the attendant loss of parasympathetic restraint is partly responsible for the high rate of malignant ventricular arrhythmias and sudden death that are characteristic of CHF. 60 Experimental evidence indicates that enalapril increases the cardiac refractoriness, 61 and ACE inhibitors have long been known to diminish the rate of arrhythmias in myocardial ischaemia and CHF, 62 ,63 a finding attributed partly to A II withdrawal and partly to potentiation of bradykinin. 64 Blockade of AT 1 receptors appears to be as efficacious as ACE inhibition for long-term cardioprotection of patients with CHF. 65, 66 If these results are confirmed by further clinical trials, they will firmly establish the multifaceted cardioprotective role of A II inhibition.
Pro-inflammatory activity
In recent years, it has become apparent that a major factor in promoting atherogenesis and arterial obstructive disease is a chronic inflammatory process. Angiotensin II was shown to enhance the activity of the transcription factor nuclear factor (NF)-B, the expression of pro-inflammatory molecules, such as the vascular cell adhesion molecule, and the release of cytokines, such as interleukin-6.
67,68 Such pro-inflammatory activity would be expected to act as an additional cardiovascular risk factor and further enhance the progression of atherosclerotic arterial damage.
Conclusions
This brief overview has highlighted several mechanisms by which A II can damage the heart. Some of them are now well established and universally accepted, because they have been demonstrated by rigorously controlled experiments and are intuitively consistent with the long-known effects of the hormone: acute myocardial necrosis and LVH fall into this category. Others are still conjectural, based on logical hypotheses whose actual effect remains to be proven: examples are the putative oxidative, procoagulant and pro-inflammatory properties of A II. Undoubtedly, continuing research will uncover additional, as yet unsuspected, mechanisms that may explain and amplify new findings in this stillevolving field. As sometimes happens in medical progress, early experimental animal and clinical studies demonstrated the destructive influence of A II and the beneficial effect of its blockade on cardiovascular tissues, whereas basic research is still exploring theories to explain the mechanisms that have led to these phenomena.
